Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引：0
|
作者：
Katalinic, D. [1 ]
机构：
[1] JJ Strossmayer Univ Osijek, Fac Med, Dept Internal Med, Zagreb, Croatia
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
772
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [31] BCR-ABL1 RATIO LOG REDUCTION IS A BETTER PREDICTOR OF MAJOR MOLECULAR RESPONSE (MMR) THAN 10% RATIO CUT-OFF AT 3 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
    Del Orbe, R.
    Pinan, A.
    Zamora, M.
    Landeta, E.
    Amarika, I.
    Amutio, E.
    Garcia Ruiz, J. C.
    HAEMATOLOGICA, 2014, 99 : 78 - 78
  • [32] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Eiring, A. M.
    Khorashad, J. S.
    Anderson, D. J.
    Yu, F.
    Redwine, H. M.
    Mason, C. C.
    Reynolds, K. R.
    Clair, P. M.
    Gantz, K. C.
    Zhang, T. Y.
    Pomicter, A. D.
    Kraft, I. L.
    Bowler, A. D.
    Johnson, K.
    Mac Partlin, M.
    O'Hare, T.
    Deininger, M. W.
    LEUKEMIA, 2015, 29 (12) : 2328 - 2337
  • [33] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    A M Eiring
    J S Khorashad
    D J Anderson
    F Yu
    H M Redwine
    C C Mason
    K R Reynolds
    P M Clair
    K C Gantz
    T Y Zhang
    A D Pomicter
    I L Kraft
    A D Bowler
    K Johnson
    M Mac Partlin
    T O'Hare
    M W Deininger
    Leukemia, 2015, 29 : 2328 - 2337
  • [34] BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
    Cai, Zhimei
    Jia, Xiting
    Zi, Jie
    Song, Huihui
    Wang, Shujun
    McGrath, Mary
    Zhao, Lidong
    Song, Chunhua
    Ge, Zheng
    JOURNAL OF CANCER, 2020, 11 (08): : 2234 - 2240
  • [35] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Eide, Christopher A.
    Bottomly, Daniel
    Savage, Samantha L.
    White, Libbey
    Wilmot, Beth
    Schultz, Anna M. Reister
    Uchida, Kimberly A.
    Agarwal, Anupriya
    Traer, Elie
    Beppu, Lan
    Sala-Torra, Olga
    Radich, Jerald P.
    Eickelberg, Garrett
    Press, Richard D.
    Loriaux, Marc M.
    Tantravahi, Srinivas K.
    Pomicter, Anthony D.
    Zabriskie, Matthew S.
    Deininger, Michael W.
    O'Hare, Thomas
    Tyner, Jeffrey W.
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    BLOOD, 2016, 128 (22)
  • [36] BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
    Song, Hye-young
    Noh, Hayeon
    Choi, Soo Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kee, Kyung-Mi
    Yoo, Hea-Lyun
    Lee, Mi-young
    Kang, Ki-Hoon
    Suh, Ji-Hyung
    Yang, Seon-young
    Jang, Eun-Jung
    Lee, Jangik, I
    Kim, Dong-Wook
    CANCER MEDICINE, 2018, 7 (10): : 5107 - 5117
  • [37] The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
    Jabbour, Elias J.
    Sasaki, Koji
    Haddad, Fadi G.
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jain, Nitin
    Yilmaz, Musa
    DiNardo, Courtney D.
    Patel, Keyur P.
    Kanagal-Shamanna, Rashmi
    Champlin, Richard
    Khouri, Issa F.
    Dellasala, Sara
    Pierce, Sherry A.
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 658 - 665
  • [38] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [39] Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors
    Lin, Jay
    Makenbaeva, Dinara
    Lingohr-Smith, Melissa
    Bilmes, Robyn
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 687 - 691
  • [40] ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE
    El Missiry, M.
    Hjorth-hansen, H.
    Richter, J.
    Olson-Stromberg, U.
    Stenke, L.
    Porkka, K.
    Kreutzmann, A.
    Mustjoki, S.
    HAEMATOLOGICA, 2016, 101 : 63 - 63
12345